We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+0.42%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
+$499M
Cap. Flow
+$505M
Cap. Flow %
26.59%
Top 10 Hldgs %
45.18%
Holding
85
New
22
Increased
26
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$130M
2
FOLD
Amicus Therapeutics
FOLD
+$49.2M
3
ALC icon
Alcon
ALC
+$47.1M
4
RVMD icon
Revolution Medicines
RVMD
+$46.1M
5
EXAS
Exact Sciences
EXAS
+$35.6M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$82M
2
URGN icon
UroGen Pharma
URGN
+$23.8M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$18.1M
4
LQDA icon
Liquidia Corp
LQDA
+$18.1M
5
ESTA icon
Establishment Labs
ESTA
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$181M 9.53%
2,750,000
+362,280
+15% +$22.6M
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$16.1B
$127M 6.7%
+1,200,000
New +$130M
CYTK icon
3
Cytokinetics
CYTK
$10.8B
$98.3M 5.18%
2,975,000
+384,469
+15% +$13.4M
NUVL
4
DELISTED
Nuvalent
NUVL
$82M 4.32%
1,075,000
– –
VERA icon
5
Vera Therapeutics
VERA
$2.39B
$73M 3.85%
3,100,000
+600,000
+24% +$13.5M
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$68.2M 3.59%
11,900,000
+7,625,000
+178% +$49.2M
XENE icon
7
Xenon Pharmaceuticals
XENE
$6.28B
$62.6M 3.3%
2,000,000
+700,000
+54% +$22.8M
DNTH icon
8
Dianthus Therapeutics
DNTH
$5.55B
$59.6M 3.14%
3,200,000
+1,499,931
+88% +$28.1M
SRRK icon
9
Scholar Rock
SRRK
$5.92B
$53.1M 2.8%
1,500,000
+200,000
+15% +$6.28M
KALV
10
DELISTED
KalVista Pharmaceuticals
KALV
$52.9M 2.78%
4,675,000
-76,292
-2% -$933K
GEHC icon
11
GE HealthCare
GEHC
$29.2B
$51.8M 2.73%
700,000
+495,870
+243% +$34.5M
QURE icon
12
uniQure
QURE
$2.52B
$51.6M 2.72%
3,700,000
-1,092,572
-23% -$14.7M
BCAX
13
Bicara Therapeutics
BCAX
$1.77B
$46.5M 2.45%
5,000,000
+2,231,025
+81% +$26.6M
ALC icon
14
Alcon
ALC
$33.7B
$46.3M 2.44%
+525,000
New +$47.1M
RVMD icon
15
Revolution Medicines
RVMD
$39.1B
$44.1M 2.32%
+1,200,000
New +$46.1M
CRNX icon
16
Crinetics Pharmaceuticals
CRNX
$8.88B
$43.1M 2.27%
1,500,000
– –
EXAS
17
DELISTED
Exact Sciences
EXAS
$37.2M 1.96%
+700,000
New +$35.6M
CLDX icon
18
Celldex Therapeutics
CLDX
$2.79B
$35.6M 1.88%
1,750,000
+1,551,354
+781% +$30.2M
ASND icon
19
Ascendis Pharma A/S
ASND
$16.7B
$34.5M 1.82%
200,000
+49,858
+33% +$8.12M
IMTX icon
20
Immatics
IMTX
$1.19B
$33.6M 1.77%
6,250,000
-942,700
-13% -$4.68M
GERN icon
21
Geron
GERN
$930M
$33.5M 1.77%
23,775,000
+1,769,660
+8% +$2.51M
GMED icon
22
Globus Medical
GMED
$10.9B
$29.5M 1.55%
500,000
+300,000
+150% +$19.4M
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$12B
$27.5M 1.45%
+500,000
New +$29.4M
MLTX icon
24
MoonLake Immunotherapeutics
MLTX
$1.59B
$26M 1.37%
550,000
+350,000
+175% +$14.3M
TYRA icon
25
Tyra Biosciences
TYRA
$1.84B
$25.4M 1.34%
2,655,000
-224,829
-8% -$2.14M
1
2 3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Vestal Point Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Vestal Point Capital held 85 positions worth $1.9B, up 36% from $1.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Vestal Point Capital deployed $505M of net new capital in Q2 2025, opening 22 new positions and adding to 26 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 1,200,000 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was uniQure, an estimated $14.7M trimmed.

  • Vestal Point Capital's largest Q2 2025 buy was Jazz Pharmaceuticals: 1,200,000 shares worth $127M.
  • Vestal Point Capital added most to Amicus Therapeutics in Q2 2025, an estimated $49.2M increase.
  • Vestal Point Capital's biggest Q2 2025 reduction was uniQure, cutting an estimated $14.7M.
  • Vestal Point Capital fully exited Insmed in Q2 2025, selling an estimated $82M.
  • Vestal Point Capital's ten largest holdings make up 45% of its $1.9B portfolio in Q2 2025.
  • Vestal Point Capital opened 22 new positions and closed 13 in Q2 2025.
  • Vestal Point Capital's portfolio value rose 36% quarter-over-quarter to $1.9B.

Based on Vestal Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.